These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 11477322

  • 1. Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.
    Marzolini C, Buclin T, Decosterd LA, Biollaz J, Telenti A.
    Ther Drug Monit; 2001 Aug; 23(4):394-8. PubMed ID: 11477322
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
    Gathe JC, Ive P, Wood R, Schürmann D, Bellos NC, DeJesus E, Gladysz A, Garris C, Yeo J.
    AIDS; 2004 Jul 23; 18(11):1529-37. PubMed ID: 15238771
    [Abstract] [Full Text] [Related]

  • 8. Simplifying drug regimens.
    HIV Hotline; 1998 Mar 23; 8(1):11. PubMed ID: 11365353
    [Abstract] [Full Text] [Related]

  • 9. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
    Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, Le Camus C, Saux MC, Fleury HJ, Pellegrin JL.
    AIDS; 2002 Jul 05; 16(10):1331-40. PubMed ID: 12131209
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.
    Villani P, Floridia M, Pirillo MF, Cusato M, Tamburrini E, Cavaliere AF, Guaraldi G, Vanzini C, Molinari A, degli Antoni A, Regazzi M.
    Br J Clin Pharmacol; 2006 Sep 05; 62(3):309-15. PubMed ID: 16934047
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.
    van Rossum AM, Bergshoeff AS, Fraaij PL, Hugen PW, Hartwig NG, Geelen SP, Wolfs TF, Weemaes CM, De Groot R, Burger DM.
    Pediatr Infect Dis J; 2002 Aug 05; 21(8):743-7. PubMed ID: 12192162
    [Abstract] [Full Text] [Related]

  • 15. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
    Ford J, Cornforth D, Hoggard PG, Cuthbertson Z, Meaden ER, Williams I, Johnson M, Daniels E, Hsyu P, Back DJ, Khoo SH.
    Antivir Ther; 2004 Feb 05; 9(1):77-84. PubMed ID: 15040539
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Twice-daily dosing of Nelfinavir approved.
    Res Initiat Treat Action; 1999 Dec 05; 5(5):22. PubMed ID: 11366888
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377.
    Floren LC, Wiznia A, Hayashi S, Jayewardene A, Stanley K, Johnson G, Nachman S, Krogstad P, Aweeka FT, Pediatric AIDS Clinical Trials Group 377 Protocol Team.
    Pediatrics; 2003 Sep 05; 112(3 Pt 1):e220-7. PubMed ID: 12949316
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.